Educational Stock Research Review: Teva Pharma Industries Ltd ADR (TEVA)
Welcome to this detailed educational research review of Teva Pharma Industries Ltd ADR (TEVA). This article is designed to help investors understand how to evaluate a company using the quantitative screening methodology employed by StockValueFinder.com. Rather than providing a simple "buy" or "sell" recommendation, this guide uses the specific financial metrics of Teva Pharma Industries Ltd ADR to teach you how to identify high-quality businesses and avoid potential value traps.
Teva Pharma Industries Ltd ADR operates within the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. For any investor looking at the pharmaceutical space, it is critical to balance the growth potential of new drugs against the financial stability of the company's balance sheet. In this review, we will break down the StockValueFinder score and the individual tests that lead to the final rating.
Why the StockValueFinder Score Matters
The StockValueFinder system assigns a numerical score to stocks based on how many fundamental "tests" a company passes. These tests cover profitability, debt management, valuation, and earnings consistency.
Teva Pharma Industries Ltd ADR has a StockValueFinder score of 13%. In this system, a high score (typically 70% or above) indicates a company that meets most of the strict criteria for quality and value. A low score suggests that the company fails several critical financial health checks. Because TEVA scored only 13%, the system has assigned it a rating of AVOID.
Understanding this score is the first step in educational investing. A low score does not necessarily mean a company is going bankrupt, but it does indicate that the company does not currently meet the quantitative standards for a "high-quality" value investment.
EPS Strength and Consistency
Earnings Per Share (EPS) is a primary indicator of a company's profitability. It tells investors how much profit is allocated to each outstanding share of common stock. More important than a single year's EPS, however, is consistency. A company that grows its EPS steadily over several years is generally more predictable and less risky than one with volatile earnings.
In the case of Teva Pharma Industries Ltd ADR, the system recorded that the EPS test "Did not pass." While detailed historical EPS values were not supplied for this specific report, the failure of this test indicates that the company's earnings history does not meet the stability or growth thresholds required by the StockValueFinder screen.
**Educational Example:** Imagine Company A has an EPS of $1.00, $1.10, and $1.20 over three years. This shows a consistent upward trend. Now imagine Company B has an EPS of $2.00, -$0.50, and $0.10. Even if Company B had one very high year, the volatility makes it a riskier bet. TEVA's failure of this test suggests a lack of the consistency seen in Company A.
ROIC and Capital Efficiency
Return on Invested Capital (ROIC) is one of the most important metrics for determining if a company is actually creating value. ROIC measures how efficiently a company uses its capital (both debt and equity) to generate profits.
Teva Pharma Industries Ltd ADR has an ROIC of 5.58%.
From an educational standpoint, StockValueFinder generally prefers an ROIC of 10% or higher. An ROIC above 10% suggests that the company is generating a healthy return on the money it invests back into its business. An ROIC below 10%—and specifically one as low as 5.58%—indicates that the company is not utilizing its capital efficiently.
**Educational Example:** If a company borrows money at 6% interest to invest in a project that only returns 5.58% (the ROIC), the company is actually losing value on that investment. A company with a 15% ROIC is using its capital far more effectively than one with a 4% ROIC, as it creates more profit for every dollar invested. Because TEVA's ROIC is 5.58%, it failed this test.
Interest Coverage and Financial Safety
Interest coverage is a solvency ratio that describes how easily a company can pay interest on its outstanding debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses.
The system recorded that Teva Pharma Industries Ltd ADR "Did not pass" the interest coverage test. StockValueFinder typically looks for an interest coverage ratio of 6 or higher. A ratio of 6 means the company earns six times more than it owes in interest payments, providing a significant cushion if earnings happen to drop.
When a company fails this test, it suggests that a larger portion of its operating income is being consumed by interest payments, leaving less room for error or reinvestment.
**Educational Example:** Consider two companies. Company X has an interest coverage of 8x, meaning it can handle a significant drop in revenue and still pay its lenders. Company Y has an interest coverage of 2x; if its revenue drops slightly, it may struggle to make its interest payments. TEVA's failure here indicates a lack of the safety margin found in Company X.
Debt Payback and Balance Sheet Discipline
While the total amount of debt is important, the "Debt Payback" metric is more useful because it puts debt in the context of cash flow. Debt payback represents the number of years it would take for a company to pay off its total debt if it dedicated its current earnings to debt reduction.
Teva Pharma Industries Ltd ADR has a debt payback period of 13.05 years.
For a stock to be considered fundamentally strong, StockValueFinder prefers a debt payback period of 3 years or less. A payback period of 13.05 years is considered weak and risky because it indicates a very heavy debt load relative to the company's ability to generate cash.
**Educational Example:** If you have $3,000 in debt and earn $1,000 a year in extra cash, your payback period is 3 years. This is manageable. If you have $13,000 in debt and earn the same $1,000 a year, your payback period is 13 years. The latter scenario is much riskier because you are exposed to interest rate changes and economic downturns for a much longer period. TEVA failed this test due to its 13.05-year payback period.
P/E Ratio and Valuation Discipline
The Price-to-Earnings (P/E) ratio tells an investor how much they are paying for every $1 of profit the company generates. It is a measure of valuation.
Teva Pharma Industries Ltd ADR has a P/E ratio of 65.68.
In a value-oriented strategy, StockValueFinder prefers a P/E ratio of 15 or lower. A high P/E ratio means the stock is expensive relative to its current earnings. A P/E of 65.68 is significantly higher than the preferred threshold of 15, meaning investors are paying a high premium for the stock.
**Educational Example:** If Company A has a P/E of 8 and Company B has a P/E of 40, Company A is more "value-oriented." Assuming both companies have similar growth and quality, Company A is a cheaper way to buy the same amount of earnings. Because TEVA's P/E is 65.68, it failed the valuation test.
Moving Average Trend and Entry Timing
While the previous sections focused on "what" to buy (fundamentals), the moving average trend focuses on "when" to buy (technical timing).
Teva Pharma Industries Ltd ADR currently shows a "BUY TREND" based on its moving average signal. This means the stock price is currently trending upward. However, it is vital to understand that a "BUY TREND" is a timing signal, not a fundamental endorsement. A stock can be in a buy trend even if its fundamentals are poor; this often happens during speculative rallies or market shifts.
Regarding specific entry points
– Entry signal: N/A – Entry status: N/A – Limit buy idea: N/A – Pullback zone: N/A – Risk stop / trend risk level: N/A
These fields are marked as N/A (Not Available). In an educational context, these levels are used as reference points to help investors avoid "chasing" a stock that has already climbed too high. Without a defined pullback zone or risk stop, an investor has no quantitative guide for where the trend becomes unsustainable.
Overall Financial Strengths and Weaknesses
When we aggregate the data for Teva Pharma Industries Ltd ADR, a clear pattern emerges.
**Strengths:** The only positive metric provided is the technical "BUY TREND." This indicates that the market is currently pushing the price higher (Recent price: $39.41), regardless of the underlying financial health.
**Weaknesses:** The company failed every single fundamental test conducted by the StockValueFinder system: 1. **Profitability:** Failed the EPS test and the ROIC test (5.58% vs. the preferred 10%+). 2. **Solvency:** Failed the Interest Coverage test and the Debt Payback test (13.05 years vs. the preferred 3 years or less). 3. **Valuation:** Failed the P/E test (65.68 vs. the preferred 15 or lower).
Risks and Limitations
Investing in a company with these metrics carries several quantitative risks. First, the high debt payback period (13.05 years) and failed interest coverage test suggest that the company is heavily burdened by debt, which can limit its ability to innovate or weather an economic downturn.
Second, the low ROIC (5.58%) suggests that the company is not generating a high return on its investments, which can lead to stagnation over the long term.
Third, the high P/E ratio (65.68) combined with a low StockValueFinder score (13%) creates a "valuation gap." This means the stock is trading at a high price despite failing the majority of the quality and value screens.
Educational Conclusion
Teva Pharma Industries Ltd ADR (TEVA) serves as an excellent educational example of why it is important to look beyond the stock price trend. While the moving average shows a "BUY TREND," the fundamental data tells a different story.
A disciplined investor looks for a "convergence" of factors: strong earnings consistency, high ROIC, low debt, and a reasonable P/E ratio. When a stock fails all these tests—as TEVA has in this screen—the StockValueFinder system assigns a low score (13%) and an AVOID rating. This process teaches us that a rising stock price does not always equal a high-quality investment.
This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.
Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings
Specializing in global financial markets, macroeconomic trends, and equity valuation, Omar Gemani brings a disciplined, research-driven perspective to investment analysis. His editorial approach emphasizes company fundamentals, earnings sustainability, financial strength, and long-term growth potential. Combining fundamental analysis with broader economic indicators, Omar evaluates investment opportunities while highlighting market uncertainty, valuation risks, and the importance of capital preservation.